

GLOBAL HEALTH PATLIPUTRA PRIVATE LIMITED

January 23, 2023

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action
Long Term Bank Facilities	365.00	CARE A; Positive	Assigned

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

The rating assigned to Global Health Patliputra Pvt Ltd (GHPPL) derives strength from parental support, i.e. Global Health Limited (GHL), also known as Medanta group, and its experienced and qualified promoter, Dr Naresh Trehan.

GHPPL was established by GHL to execute and operate 'Jay Prabha Medanta Super Speciality Hospital' in Patna. This was a greenfield project whose operations commenced in H2FY22 providing geographical diversification to GHL by targeting Eastern region of India. The hospital benefits immensely from the healthy reputation of Medanta group of hospitals and its promoter, Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon which mitigates challenges in bed occupancy rates initially. The group has successfully executed and quickly ramped up its operations historically, with latest being the Lucknow hospital housed under GHL's subsidiary - Medanta Holdings Pvt Ltd (MHPL). Further, the arrangement with Government of Bihar reserving 25% beds under its schemes, further provides support for moderate bed occupancy rates over the medium term. The corporate guarantee and shortfall undertaking along with significant equity infusion upfront accentuates the strong financial support from the parent mitigating below average debt coverage metrics at standalone level. However, being in healthcare services, both parent, GHL, and GHPPL are exposed to regulatory risk.

CARE has also factored in the successful initial public offer (IPO) of GHL, the parent of GHPPL having raised ~Rs.500 crore in fresh issue in November 2022, out of which atleast 75% of the proceeds will be utilized in prepayment of its term loans, present in its subsidiaries i.e. GHPPL & MHPL. The utilization of those proceeds would be a key monitorable.

Rating sensitivities: Factors likely to lead to rating actions

Positive factors

- Improvement in the credit risk profile of the parent company
- Completion of the project and PBILDT margins of 15% upwards, and thus contributing meaningfully to the overall profitability of GHL.
- Substantial reduction in debt levels and improvement in debt coverage indicators.

Negative factors

- Deterioration in the credit profile of the parent.
- Any change in stance on supporting GHPPL by the parent company or reduction in shareholding by any means where GHL loses control over GHPPL.
- Significantly lower than un-envisaged levels of revenues and operating margin (i.e. below 8-10%) over the long term

Analytical approach: Standalone.

The ratings however factor in the strong Operational, Management and financial linkages with the Parent entity (GHL) owing to GHPPL being ~100% subsidiary of GHL with **Common management, Board of directors, Brand name and cash flow fungibility**. Further, GHL has provided Corporate Guarantee and Shortfall Undertaking to the banker of GHPPL.

Note: Further for Analysing GHL- Consolidated financials of GHL are considered which also incorporates the support to be extended to GHPPL. The list of subsidiaries is as mentioned in Annexure – 5.

Outlook: Positive

'Positive' outlook to the long-term rating of GHPPL underscores expectations of sustained improvement in the credit profile of the parent company over the medium term, particularly its business risk profile, and its benefit percolating to GHL's subsidiaries including GHPPL. GHPPL is expected to quickly scale up its Patna hospital operations supported by incremental addition in installed beds and improvement in bed occupancy rate, which are majorly driven by the support from the parent company, both operational and financial in nature.

The outlook may be revised to 'Stable' in case parent company's overall credit profile doesn't incrementally strengthen as envisaged or at standalone level GHPPL's profile operations requires longer timeframe to stabilize.

Key strengths

Strong parentage, experienced & highly qualified ultimate promoter: Global Health Patliputra Pvt Ltd is a wholly owned subsidiary of GHL, considering shares allotted to Dr. Naresh Trehan as a nominee of GHL, which operates Medanta group of multi-speciality hospitals located across Gurugram (Haryana), Lucknow (Uttar Pradesh), Indore (Madhya Pradesh), Ranchi (Jharkhand)

¹Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications

and recently opened hospital in Patna (Bihar). GHL was incorporated by Dr Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon in 2004. GHPPL's operations will benefit immensely from reputation of Dr. Trehan who also has over two decades of experience in Escorts Heart Institute & Research Centre. His expertise and standing has been instrumental in developing a strong reputation for Medanta group of hospitals, particularly in National Capital Region.

The company has two wholly-owned subsidiaries, namely, Medanta Holdings Private Limited (MHPL) and GHPPL. MHPL and GHPPL house Medanta group's Lucknow and Patna hospitals, respectively. As on June 30, 2022, the group's cumulative bed capacity stood at ~2500 as on June 30, 2022, and is expected to increase its bed capacity to 3,500 beds by FY25 through greenfield and brownfield expansions.

Execution and operational support by the parent: GHPPL is expected to draw synergies from existing chain of hospitals of the parent. The reputation of the Medanta group of hospitals and Dr. Naresh Tehran along with the referrals from GHL's diagnostic centres are expected to help the company quickly ramp up its bed occupancy. Apart from that, GHL has existing supply chain which may also aid the Patna operations. The establishment of Patna hospital has been largely supported by GHL, having infused Rs.297 crore as on March 31, 2022. The parent has extended both corporate guarantee and shortfall undertaking for the bank loan facilities advanced to GHPPL along with infusion of funds in FY23 as well.

Moderately low project risk: GHPPL had commenced its operations in H2FY22 with 100 beds and has received permission for 300 beds from Govt of Bihar as of July 7, 2022. Currently, the Patna hospital has 330 bed capacity. The hospital is expected to install additional bed capacity upto 650 in total over the medium term which are expected to come up in phases. Considering the hospital has been operationalized, there is limited project risk emanating from expansion of hospital beds.

Key weaknesses

Nascent stage of operations leading to challenges in bed occupancy rate: GHPPL started its commercial operations in H2FY22 and has a relatively short track record of operations. The company's scale of operations has remained small marked by net sales of Rs.24 crore during FY22 and Rs.28 cr in Q1FY23. Furthermore, post project implementation risk in the form of stabilization of the facilities to achieve the envisaged scale of business remains crucial for GHPPL. With the inching up of occupancy rate every quarter, the company is expected to book revenue around Rs.150 crore in FY23 and continue its growth trajectory in line with expected enhancement of installed beds. The ability to scale up would also reflect on its profitability and hence both are key monitorables.

Below average debt coverage metrics at standalone level: Subdued profitability during initial years of operations is expected to keep debt coverage metrics below average since the gestation period in hospitals is relatively long. However, the company has the financial flexibility derived by the healthy cash & cash equivalents with the parent company i.e. GHL.

Exposure to regulatory risk: GHPPL operates in a regulated industry that has witnessed continuous regulatory intervention during the past couple of years. There have been regulations such as the capping of stent prices and knee implants and stricter compliance norms. Any such future regulations may have an adverse impact on the company's and the parent's profitability, and thus, will remain an important monitorable.

Liquidity: Adequate

Adequate liquidity is driven by continuous equity infusion from the parent which has strong liquidity. Corporate guarantee and shortfall undertaking has been extended by the parent to GHPPL's lender as well. The company's term loan repayments are ballooning in nature (in the range of Rs.20-32 crore during FY24 and FY25) and initially the parent is expected to support its servicing till the operations of the company stabilize.

The parent company's gross cash accrual are expected at Rs 330-400 crore per annum over FY23 to FY25 which is expected to cover its repayment obligations of about Rs.90-120 cr annually till FY25. Liquidity is supported by healthy cash & cash equivalents of around Rs.500 crore as on March 31, 2022. Further the company has received additional Rs.500 crore from IPO in fresh issue which will be utilized to reduce debt and other general corporate purposes. This along with healthy capital structure estimated after reduction of debt, provides significant headroom to raise debt if required.

Applicable criteria

[Policy on default recognition](#)

[Consolidation](#)

[Factoring Linkages Parent Sub JV Group](#)

[Financial Ratios – Non financial Sector](#)

[Liquidity Analysis of Non-financial sector entities](#)

[Rating Outlook and Credit Watch](#)

[Hospital](#)

[Service Sector Companies](#)

[Policy on Withdrawal of Ratings](#)

About the company - GHPPL

GHPPL is part of the Medanta Group and a wholly-owned subsidiary of Global Health Limited (GHL), the group's flagship company. GHPPL owns and operates the group's newly launched Jay Prabha Medanta Super Speciality Hospital in Patna, Bihar. The hospital's OPD facility was launched in 2020 whereas its IPD facility was inaugurated in H2FY22. As on June 30, 2022, the installed beds were 228 and is expected to scale upto 650 beds over the medium to long term.

Brief Financials (₹ crore)	March 31, 2021 (A)	March 31, 2022 (A)	Q1FY23 (UA)
Total operating income	0.23	25.28	28.02
PBILDT	-6.15	-25.97	-112.58
PAT	-16.35	-45.81	NA
Overall gearing (times)	1.58	1.62	
Interest coverage (times)	-0.80	-2.20	

A: Audited; UA: Un-Audited

About the parent company

GHL was incorporated as 'Global Health Private Limited' on August 13, 2004 by Dr Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon. A world-class, super-specialty, tertiary-care hospital in Gurugram, Medanta commenced operations in November 2009 and currently has cumulative bed count at over 2,467 as on June 30, 2022. The company has two wholly-owned subsidiaries, namely, Medanta Holdings Private Limited (MHPL) and GHPPL. MHPL and GHPPL house Medanta group's Lucknow and Patna hospitals, respectively, both of which commenced operations in H1FY21 and H2FY22, respectively.

Brief Financials (₹ crore)	March 31, 2021 (A)	March 31, 2022 (A)	Q1FY23 (UA)
Total operating income	1435.28	2161.54	617.21
PBILDT	194.25	457.94	132.31
PAT	28.81	196.20	58.71
Overall gearing (times)	0.68	0.69	0.63
Interest coverage (times)	2.67	5.30	7.14

A: Audited; UA: Un-Audited

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating history for the last three years: Please refer Annexure-2

Covenants of the rated instruments/facilities: Not Applicable

Complexity level of the various instruments rated: Annexure-3

Lender details: Annexure-4

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fund-based - LT-Term Loan	-	-	-	12-07-2031	365.00	CARE A; Positive

Annexure-2: Rating history for the last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022	Date(s) and Rating(s) assigned in 2020-2021	Date(s) and Rating(s) assigned in 2019-2020
1	Fund-based - LT-Term Loan	LT	365.00	CARE A; Positive	-	-	-	-

*Long term/Short term.

Annexure-3: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Term Loan	Simple

Annexure-4: Lender details

To view the lender wise details of bank facilities please [click here](#)

Note on the complexity levels of the rated instruments: CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

Annexure-5: List of Subsidiaries consolidated for GHL

Name of Entity	% Ownership	Relation with GHL
Medanta Holdings Private Limited (MHPL)	Almost 100%	Subsidiary
Global Health Patliputra Private Limited (GHPPL)	Almost 100%	Subsidiary
GHL Pharma & Diagnostic Private Limited (GHL Pharma)	Almost 100%	Subsidiary

Contact us**Media contact**

Name: Mradul Mishra

Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in**Analyst contact**

Name: Ravleen Sethi

Phone: 9818032229

E-mail: ravleen.sethi@careedge.in**Relationship contact**

Name: Dinesh Sharma

Phone: +91-11-4533 3200

E-mail: dinesh.sharma@careedge.in**About us:**

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

**For the detailed Rationale Report and subscription information,
please visit www.careedge.in**